Readline, a Shenzhen-based bio-pharmaceutical firm, has secured 300 million yuan ($43 million) in a Series B round led by CoStone Capital, the firm announced via its WeChat channel on Friday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
